{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:21:12Z","timestamp":1785414072232,"version":"3.56.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jhep.2024.03.011","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:11:23Z","timestamp":1710591083000},"page":"678-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8218-192X","authenticated-orcid":false,"given":"Mark","family":"Thursz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-2025","authenticated-orcid":false,"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.03.011_bib1","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.03.011_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 Days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.03.011_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhep.2024.03.011_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.011_bib5","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.011_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized-controlled trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.03.011_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.03.011_bib8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.03.011_bib9","first-page":"86a","article-title":"Combination of amoxicillin\/clavulanate and prednisolone in severe alcoholic hepatitis: results of the antibiocor randomized controlled trial","volume":"74","author":"Louvet","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.03.011_bib10","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.03.011_bib11","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/apt.17733","article-title":"In Severe alcohol-related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL-8 and micro-RNAs","volume":"58","author":"Tyson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.03.011_bib12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1681\/ASN.0000000000000191","article-title":"Divergent actions of renal tubular and endothelial type 1 IL-1 receptor signaling in toxin-induced AKI","volume":"34","author":"Ren","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2024.03.011_bib13","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(22)00480-9","article-title":"Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)","volume":"77","author":"Vergis","year":"2022","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824001636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:50:06Z","timestamp":1759175406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824001636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0168827824001636"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting IL-1 in severe alcohol-related hepatitis: How many frogs will we need to kiss to find an effective therapy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.031","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}